Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkImmune Responses to SARS-CoV-2 Among Patients With Cancer

In this issue of JAMA Oncology, two groups investigate the immune response to SARS-CoV-2, by proxy of antibody assays, in patients with solid malignant neoplasms who were undergoing active cancer therapy. With the concern that patients with cancer may not mount a robust protective immune response to SARS-CoV-2 infection or vaccination, the studies attempt to discover what seropositivity can tell us.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form